{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:25:07Z","timestamp":1793744707397,"version":"4.6.1"},"reference-count":227,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Immunol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1038\/s41590-025-02096-9","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T10:16:59Z","timestamp":1740737819000},"page":"351-365","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The rewired immune microenvironment in leukemia"],"prefix":"10.1038","volume":"26","author":[{"given":"Zoe","family":"Ciantra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varvara","family":"Paraskevopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6857-1035","authenticated-orcid":false,"given":"Iannis","family":"Aifantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"2096_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc.2016.112","volume":"17","author":"AS Sperling","year":"2017","unstructured":"Sperling, A. S., Gibson, C. J. & Ebert, B. L. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat. Rev. Cancer 17, 5\u201319 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"2096_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3389\/fonc.2017.00263","volume":"7","author":"MR Corces","year":"2017","unstructured":"Corces, M. R., Chang, H. Y. & Majeti, R. Preleukemic hematopoietic stem cells in human acute myeloid leukemia. Front. Oncol. 7, 263 (2017).","journal-title":"Front. Oncol."},{"key":"2096_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian, H. et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 11, 41 (2021).","journal-title":"Blood Cancer J."},{"key":"2096_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow, M. R. et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N. Engl. J. Med. 391, 320\u2013333 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2096_CR5","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.trecan.2019.07.009","volume":"5","author":"MT Witkowski","year":"2019","unstructured":"Witkowski, M. T., Lasry, A., Carroll, W. L. & Aifantis, I. Immune-tased therapies in acute leukemia. Trends Cancer 5, 604\u2013618 (2019).","journal-title":"Trends Cancer"},{"key":"2096_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41586-019-1104-8","volume":"569","author":"AN Tikhonova","year":"2019","unstructured":"Tikhonova, A. N. et al. The bone marrow microenvironment at single-cell resolution. Nature 569, 222\u2013228 (2019).","journal-title":"Nature"},{"key":"2096_CR7","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.cell.2019.04.040","volume":"177","author":"N Baryawno","year":"2019","unstructured":"Baryawno, N. et al. A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. Cell 177, 1915\u20131932 (2019).","journal-title":"Cell"},{"key":"2096_CR8","first-page":"27","volume":"4","author":"A Lasry","year":"2023","unstructured":"Lasry, A. et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat. Cancer 4, 27\u201342 (2023).","journal-title":"Nat. Cancer"},{"key":"2096_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/leu.2017.259","volume":"32","author":"B Kumar","year":"2018","unstructured":"Kumar, B. et al. Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia 32, 575\u2013587 (2018).","journal-title":"Leukemia"},{"key":"2096_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.ccell.2020.04.015","volume":"37","author":"MT Witkowski","year":"2020","unstructured":"Witkowski, M. T. et al. Extensive remodeling of the immune microenvironment in B cell acute lymphoblastic leukemia. Cancer Cell 37, 867\u2013882 (2020).","journal-title":"Cancer Cell"},{"key":"2096_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13570-y","volume":"10","author":"G Rodriguez-Hernandez","year":"2019","unstructured":"Rodriguez-Hernandez, G. et al. Infectious stimuli promote malignant B-cell acute lymphoblastic leukemia in the absence of AID. Nat. Commun. 10, 5563 (2019).","journal-title":"Nat. Commun."},{"key":"2096_CR12","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1016\/j.celrep.2018.08.030","volume":"24","author":"S Saint Fleur-Lominy","year":"2018","unstructured":"Saint Fleur-Lominy, S. et al. STIM1 and STIM2 mediate cancer-induced inflammation in T cell acute lymphoblastic leukemia. Cell Rep. 24, 3045\u20133060 (2018).","journal-title":"Cell Rep."},{"key":"2096_CR13","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.stem.2021.03.002","volume":"28","author":"D Hormaechea-Agulla","year":"2021","unstructured":"Hormaechea-Agulla, D. et al. Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFN\u03b3 signaling. Cell Stem Cell 28, 1428\u20131442 (2021).","journal-title":"Cell Stem Cell"},{"key":"2096_CR14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41375-024-02136-7","volume":"38","author":"DW Chen","year":"2024","unstructured":"Chen, D. W. et al. Inflammatory recruitment of healthy hematopoietic stem and progenitor cells in the acute myeloid leukemia niche. Leukemia 38, 741\u2013750 (2024).","journal-title":"Leukemia"},{"key":"2096_CR15","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/ni.3160","volume":"16","author":"S Swaminathan","year":"2015","unstructured":"Swaminathan, S. et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat. Immunol. 16, 766\u2013774 (2015).","journal-title":"Nat. Immunol."},{"key":"2096_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2643-3230.BCD-23-0020","volume":"4","author":"A Nelde","year":"2023","unstructured":"Nelde, A. et al. Immune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells. Blood Cancer Discov. 4, 468\u2013489 (2023).","journal-title":"Blood Cancer Discov."},{"key":"2096_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ccell.2020.08.019","volume":"38","author":"O Dufva","year":"2020","unstructured":"Dufva, O. et al. Immunogenomic landscape of hematological malignancies. Cancer Cell 38, 424\u2013428 (2020).","journal-title":"Cancer Cell"},{"key":"2096_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","volume":"25","author":"C Toffalori","year":"2019","unstructured":"Toffalori, C. et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat. Med. 25, 603\u2013611 (2019).","journal-title":"Nat. Med."},{"key":"2096_CR19","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1016\/j.cell.2023.07.016","volume":"186","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell 186, 3903\u20133920 (2023).","journal-title":"Cell"},{"key":"2096_CR20","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-21-0502","volume":"13","author":"MH Linde","year":"2023","unstructured":"Linde, M. H. et al. Reprogramming cancer into antigen-presenting cells as a novel immunotherapy. Cancer Discov. 13, 1164\u20131185 (2023).","journal-title":"Cancer Discov."},{"key":"2096_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2020.152049","volume":"226","author":"I Antohe","year":"2021","unstructured":"Antohe, I. et al. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression. Immunobiology 226, 152049 (2021).","journal-title":"Immunobiology"},{"key":"2096_CR22","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","volume":"26","author":"A D\u2019Souza","year":"2020","unstructured":"D\u2019Souza, A. et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol. Blood Marrow Transplant. 26, e177\u2013e182 (2020).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2096_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5966\/sctm.2012-0115","volume":"2","author":"AD Sung","year":"2013","unstructured":"Sung, A. D. & Chao, N. J. Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. Stem Cells Transl. Med. 2, 25\u201332 (2013).","journal-title":"Stem Cells Transl. Med."},{"key":"2096_CR24","doi-asserted-by":"publisher","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra138 (2013).","journal-title":"Sci. Transl. Med."},{"key":"2096_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41375-023-02119-0","volume":"38","author":"M Yanada","year":"2024","unstructured":"Yanada, M. et al. Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission. Leukemia 38, 513\u2013520 (2024).","journal-title":"Leukemia"},{"key":"2096_CR26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/ph14040288","volume":"14","author":"L Jimbu","year":"2021","unstructured":"Jimbu, L. et al. Is there a place for PD-1\u2013PD-L blockade in acute myeloid leukemia? Pharmaceuticals 14, 288 (2021).","journal-title":"Pharmaceuticals"},{"key":"2096_CR27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","volume":"30","author":"C Krupka","year":"2016","unstructured":"Krupka, C. et al. Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia 30, 484\u2013491 (2016).","journal-title":"Leukemia"},{"key":"2096_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26282-z","volume":"12","author":"HA Abbas","year":"2021","unstructured":"Abbas, H. A. et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat. Commun. 12, 6071 (2021).","journal-title":"Nat. Commun."},{"key":"2096_CR29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41587-021-01089-x","volume":"40","author":"M Ali","year":"2022","unstructured":"Ali, M. et al. T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. Nat. Biotechnol. 40, 488\u2013498 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2096_CR30","doi-asserted-by":"publisher","first-page":"76902","DOI":"10.18632\/oncotarget.12357","volume":"7","author":"J Feucht","year":"2016","unstructured":"Feucht, J. et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts. Oncotarget 7, 76902\u201376919 (2016).","journal-title":"Oncotarget"},{"key":"2096_CR31","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","volume":"123","author":"MK Gleason","year":"2014","unstructured":"Gleason, M. K. et al. CD16\u00d7CD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123, 3016\u20133026 (2014).","journal-title":"Blood"},{"key":"2096_CR32","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/s43018-023-00642-8","volume":"4","author":"E Giannakopoulou","year":"2023","unstructured":"Giannakopoulou, E. et al. A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo. Nat. Cancer 4, 1474\u20131490 (2023).","journal-title":"Nat. Cancer"},{"key":"2096_CR33","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.devcel.2021.05.018","volume":"56","author":"S Comazzetto","year":"2021","unstructured":"Comazzetto, S., Shen, B. & Morrison, S. J. Niches that regulate stem cells and hematopoiesis in adult bone marrow. Dev. Cell 56, 1848\u20131860 (2021).","journal-title":"Dev. Cell"},{"key":"2096_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41568-020-0245-2","volume":"20","author":"S Mendez-Ferrer","year":"2020","unstructured":"Mendez-Ferrer, S. et al. Bone marrow niches in haematological malignancies. Nat. Rev. Cancer 20, 285\u2013298 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"2096_CR35","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nature08851","volume":"464","author":"MH Raaijmakers","year":"2010","unstructured":"Raaijmakers, M. H. et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852\u2013857 (2010).","journal-title":"Nature"},{"key":"2096_CR36","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.cell.2007.05.014","volume":"129","author":"CR Walkley","year":"2007","unstructured":"Walkley, C. R. et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor \u03b3 deficiency. Cell 129, 1097\u20131110 (2007).","journal-title":"Cell"},{"key":"2096_CR37","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.stem.2019.06.007","volume":"25","author":"YH Ho","year":"2019","unstructured":"Ho, Y. H. et al. Remodeling of bone marrow hematopoietic stem cell niches promotes myeloid cell expansion during premature or physiological aging. Cell Stem Cell 25, 407\u2013418 (2019).","journal-title":"Cell Stem Cell"},{"key":"2096_CR38","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nm.3647","volume":"20","author":"A Mendelson","year":"2014","unstructured":"Mendelson, A. & Frenette, P. S. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat. Med. 20, 833\u2013846 (2014).","journal-title":"Nat. Med."},{"key":"2096_CR39","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/s41591-018-0030-x","volume":"24","author":"M Maryanovich","year":"2019","unstructured":"Maryanovich, M. et al. Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche. Nat. Med. 24, 782\u2013791 (2019).","journal-title":"Nat. Med."},{"key":"2096_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nature13383","volume":"512","author":"L Arranz","year":"2014","unstructured":"Arranz, L. et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature 512, 78\u201381 (2014).","journal-title":"Nature"},{"key":"2096_CR41","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/s43018-023-00607-x","volume":"4","author":"E Grockowiak","year":"2023","unstructured":"Grockowiak, E. et al. Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms. Nat. Cancer 4, 1193\u20131209 (2023).","journal-title":"Nat. Cancer"},{"key":"2096_CR42","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.stemcr.2017.11.019","volume":"10","author":"R Li","year":"2018","unstructured":"Li, R. et al. TET2 loss dysregulates the behavior of bone marrow mesenchymal stromal cells and accelerates Tet2\u2212\/\u2212-driven myeloid malignancy progression. Stem Cell Rep. 10, 166\u2013179 (2018).","journal-title":"Stem Cell Rep."},{"key":"2096_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41421-017-0004-z","volume":"4","author":"P Zhang","year":"2018","unstructured":"Zhang, P. et al. Loss of ASXL1 in the bone marrow niche dysregulates hematopoietic stem and progenitor cell fates. Cell Discov. 4, 4 (2018).","journal-title":"Cell Discov."},{"key":"2096_CR44","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1158\/2159-8290.CD-22-0086","volume":"12","author":"JM SanMiguel","year":"2022","unstructured":"SanMiguel, J. M. et al. Distinct tumor necrosis factor \u03b1 receptors dictate stem cell fitness versus lineage output in Dnmt3a-mutant clonal hematopoiesis. Cancer Discov. 12, 2763\u20132773 (2022).","journal-title":"Cancer Discov."},{"key":"2096_CR45","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.stem.2014.06.020","volume":"15","author":"M Hanoun","year":"2014","unstructured":"Hanoun, M. et al. Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche. Cell Stem Cell 15, 365\u2013375 (2014).","journal-title":"Cell Stem Cell"},{"key":"2096_CR46","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ccell.2015.04.004","volume":"27","author":"RS Welner","year":"2015","unstructured":"Welner, R. S. et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell 27, 671\u2013681 (2015).","journal-title":"Cancer Cell"},{"key":"2096_CR47","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","volume":"5","author":"M Kleppe","year":"2015","unstructured":"Kleppe, M. et al. JAK\u2013STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 5, 316\u2013331 (2015).","journal-title":"Cancer Discov."},{"key":"2096_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/JLB.3MA0422-286R","volume":"112","author":"J Rios de Los Rios","year":"2022","unstructured":"Rios de Los Rios, J. et al. Acute lymphoblastic leukemia-secreted miRNAs induce a proinflammatory microenvironment and promote the activation of hematopoietic progenitors. J. Leukoc. Biol. 112, 31\u201345 (2022).","journal-title":"J. Leukoc. Biol."},{"key":"2096_CR49","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/ncb2432","volume":"14","author":"W Zhang","year":"2012","unstructured":"Zhang, W. et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat. Cell Biol. 14, 276\u2013286 (2012).","journal-title":"Nat. Cell Biol."},{"key":"2096_CR50","first-page":"666","volume":"7","author":"JC Balandran","year":"2016","unstructured":"Balandran, J. C. et al. Pro-inflammatory-related loss of CXCL12 niche promotes acute lymphoblastic leukemic progression at the expense of normal lymphopoiesis. Front. Immunol. 7, 666 (2016).","journal-title":"Front. Immunol."},{"key":"2096_CR51","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.stem.2019.02.018","volume":"24","author":"P Agarwal","year":"2019","unstructured":"Agarwal, P. et al. Mesenchymal niche-specific expression of Cxcl12 controls quiescence of treatment-resistant leukemia stem cells. Cell Stem Cell 24, 769\u2013784 (2019).","journal-title":"Cell Stem Cell"},{"key":"2096_CR52","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","volume":"13","author":"K Schepers","year":"2013","unstructured":"Schepers, K. et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 13, 285\u2013299 (2013).","journal-title":"Cell Stem Cell"},{"key":"2096_CR53","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1182\/blood-2013-05-501460","volume":"122","author":"B Laperrousaz","year":"2013","unstructured":"Laperrousaz, B. et al. Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression. Blood 122, 3767\u20133777 (2013).","journal-title":"Blood"},{"key":"2096_CR54","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","volume":"102","author":"BO Oyajobi","year":"2003","unstructured":"Oyajobi, B. O. et al. Dual effects of macrophage inflammatory protein-1\u03b1 on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 102, 311\u2013319 (2003).","journal-title":"Blood"},{"key":"2096_CR55","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/ncb3530","volume":"19","author":"M Decker","year":"2017","unstructured":"Decker, M. et al. Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis. Nat. Cell Biol. 19, 677\u2013688 (2017).","journal-title":"Nat. Cell Biol."},{"key":"2096_CR56","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.stem.2017.03.008","volume":"20","author":"RK Schneider","year":"2017","unstructured":"Schneider, R. K. et al. Gli1+ mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target. Cell Stem Cell 20, 785\u2013800 (2017).","journal-title":"Cell Stem Cell"},{"key":"2096_CR57","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2014.02.014","volume":"14","author":"H Medyouf","year":"2014","unstructured":"Medyouf, H. et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell 14, 824\u2013837 (2014).","journal-title":"Cell Stem Cell"},{"key":"2096_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15817-5","volume":"11","author":"V Barbier","year":"2020","unstructured":"Barbier, V. et al. Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance. Nat. Commun. 11, 2042 (2020).","journal-title":"Nat. Commun."},{"key":"2096_CR59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.stem.2017.11.006","volume":"22","author":"D Duarte","year":"2018","unstructured":"Duarte, D. et al. Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML. Cell Stem Cell 22, 64\u201377 (2018).","journal-title":"Cell Stem Cell"},{"key":"2096_CR60","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.ccell.2015.05.003","volume":"27","author":"D Passaro","year":"2015","unstructured":"Passaro, D. et al. CXCR4 is required for leukemia-initiating cell activity in T cell acute lymphoblastic leukemia. Cancer Cell 27, 769\u2013779 (2015).","journal-title":"Cancer Cell"},{"key":"2096_CR61","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ccell.2015.05.002","volume":"27","author":"LA Pitt","year":"2015","unstructured":"Pitt, L. A. et al. CXCL12-producing vascular endothelial niches control acute T cell leukemia maintenance. Cancer Cell 27, 755\u2013768 (2015).","journal-title":"Cancer Cell"},{"key":"2096_CR62","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ccr.2011.05.007","volume":"19","author":"T Schmidt","year":"2011","unstructured":"Schmidt, T. et al. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1+ leukemia. Cancer Cell 19, 740\u2013753 (2011).","journal-title":"Cancer Cell"},{"key":"2096_CR63","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209\u20132221 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2096_CR64","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1182\/bloodadvances.2019000792","volume":"4","author":"O Bruck","year":"2020","unstructured":"Bruck, O. et al. Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. Blood Adv. 4, 274\u2013286 (2020).","journal-title":"Blood Adv."},{"key":"2096_CR65","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1038\/s41596-021-00556-8","volume":"16","author":"S Black","year":"2021","unstructured":"Black, S. et al. CODEX multiplexed tissue imaging with DNA-conjugated antibodies. Nat. Protoc. 16, 3802\u20133835 (2021).","journal-title":"Nat. Protoc."},{"key":"2096_CR66","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1016\/j.cell.2024.04.013","volume":"187","author":"S Bandyopadhyay","year":"2024","unstructured":"Bandyopadhyay, S. et al. Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging. Cell 187, 3120\u20133140 (2024).","journal-title":"Cell"},{"key":"2096_CR67","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2017.08.001","volume":"32","author":"D Passaro","year":"2017","unstructured":"Passaro, D. et al. Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia. Cancer Cell 32, 324\u2013341 (2017).","journal-title":"Cancer Cell"},{"key":"2096_CR68","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1182\/blood-2005-01-0122","volume":"105","author":"DH Munn","year":"2005","unstructured":"Munn, D. H., Mellor, A. L., Rossi, M. & Young, J. W. Dendritic cells have the option to express IDO-mediated suppression or not. Blood 105, 2618 (2005).","journal-title":"Blood"},{"key":"2096_CR69","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","volume":"122","author":"F Mussai","year":"2013","unstructured":"Mussai, F. et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood 122, 749\u2013758 (2013).","journal-title":"Blood"},{"key":"2096_CR70","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1182\/blood-2011-08-374728","volume":"118","author":"S Serra","year":"2011","unstructured":"Serra, S. et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 118, 6141\u20136152 (2011).","journal-title":"Blood"},{"key":"2096_CR71","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjh.12774","volume":"165","author":"N Dulphy","year":"2014","unstructured":"Dulphy, N. et al. Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis. Br. J. Haematol. 165, 722\u2013725 (2014).","journal-title":"Br. J. Haematol."},{"key":"2096_CR72","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.stemcr.2017.04.019","volume":"8","author":"R Diaz de la Guardia","year":"2017","unstructured":"Diaz de la Guardia, R. et al. Detailed characterization of mesenchymal stem\/stromal cells from a large cohort of AML patients demonstrates a definitive link to treatment outcomes. Stem Cell Rep. 8, 1573\u20131586 (2017).","journal-title":"Stem Cell Rep."},{"key":"2096_CR73","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"A Carey","year":"2017","unstructured":"Carey, A. et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 18, 3204\u20133218 (2017).","journal-title":"Cell Rep."},{"key":"2096_CR74","doi-asserted-by":"publisher","first-page":"eabb8969","DOI":"10.1126\/scitranslmed.abb8969","volume":"12","author":"FM Uhl","year":"2020","unstructured":"Uhl, F. M. et al. Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. Sci. Transl. Med. 12, eabb8969 (2020).","journal-title":"Sci. Transl. Med."},{"key":"2096_CR75","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood.2022018092","volume":"141","author":"SK Mishra","year":"2023","unstructured":"Mishra, S. K., Millman, S. E. & Zhang, L. Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood 141, 1119\u20131135 (2023).","journal-title":"Blood"},{"key":"2096_CR76","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1182\/blood.2022016926","volume":"140","author":"N Vallet","year":"2022","unstructured":"Vallet, N. et al. Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation. Blood 140, 2500\u20132513 (2022).","journal-title":"Blood"},{"key":"2096_CR77","doi-asserted-by":"publisher","first-page":"103627","DOI":"10.1016\/j.ebiom.2021.103627","volume":"73","author":"ZH Wang","year":"2021","unstructured":"Wang, Z. H., Peng, W. B., Zhang, P., Yang, X. P. & Zhou, Q. Lactate in the tumour microenvironment: from immune modulation to therapy. eBioMedicine 73, 103627 (2021).","journal-title":"eBioMedicine"},{"key":"2096_CR78","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","volume":"109","author":"K Fischer","year":"2007","unstructured":"Fischer, K. et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109, 3812\u20133819 (2007).","journal-title":"Blood"},{"key":"2096_CR79","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229\u20131241 (2015).","journal-title":"Cell"},{"key":"2096_CR80","first-page":"120","volume":"38","author":"I Sari","year":"2008","unstructured":"Sari, I. et al. Disturbance of pro-oxidative\/antioxidative balance in allogeneic peripheral blood stem cell transplantation. Ann. Clin. Lab. Sci. 38, 120\u2013125 (2008).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"2096_CR81","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000337040","volume":"89","author":"S Sabuncuoglu","year":"2012","unstructured":"Sabuncuoglu, S., Oztas, Y., Cetinkaya, D. U., Ozgunes, N. & Ozgunes, H. Oxidative protein damage with carbonyl levels and nitrotyrosine expression after chemotherapy in bone marrow transplantation patients. Pharmacology 89, 283\u2013286 (2012).","journal-title":"Pharmacology"},{"key":"2096_CR82","doi-asserted-by":"publisher","first-page":"7499","DOI":"10.1074\/jbc.TM117.000257","volume":"293","author":"H Kong","year":"2018","unstructured":"Kong, H. & Chandel, N. S. Regulation of redox balance in cancer and T cells. J. Biol. Chem. 293, 7499\u20137507 (2018).","journal-title":"J. Biol. Chem."},{"key":"2096_CR83","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher, M. J. et al. Immune escape of relapsed AML cells after allogeneic transplantation. N. Engl. J. Med. 379, 2330\u20132341 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2096_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08871-1","volume":"10","author":"M Noviello","year":"2019","unstructured":"Noviello, M. et al. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat. Commun. 10, 1065 (2019).","journal-title":"Nat. Commun."},{"key":"2096_CR85","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bbmt.2018.09.037","volume":"25","author":"P Jain","year":"2019","unstructured":"Jain, P. et al. Over-expression of PD-1 does not predict leukemic relapse after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 25, 216\u2013222 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2096_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.58","volume":"5","author":"Y Kong","year":"2015","unstructured":"Kong, Y. et al. PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J. 5, e330 (2015).","journal-title":"Blood Cancer J."},{"key":"2096_CR87","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"P Williams","year":"2019","unstructured":"Williams, P. et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125, 1470\u20131481 (2019).","journal-title":"Cancer"},{"key":"2096_CR88","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and iImmunity. Cell 176, 1265\u20131281 (2019).","journal-title":"Cell"},{"key":"2096_CR89","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1158\/2159-8290.CD-21-1146","volume":"12","author":"A Yeaton","year":"2022","unstructured":"Yeaton, A. et al. The impact of inflammation-induced tumor plasticity during myeloid transformation. Cancer Discov. 12, 2392\u20132413 (2022).","journal-title":"Cancer Discov."},{"key":"2096_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00265-0","volume":"9","author":"R Guo","year":"2021","unstructured":"Guo, R. et al. Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. Biomark. Res. 9, 15 (2021).","journal-title":"Biomark. Res."},{"key":"2096_CR91","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1172\/JCI85413","volume":"126","author":"BL Mundy-Bosse","year":"2016","unstructured":"Mundy-Bosse, B. L. et al. MicroRNA-29b mediates altered innate immune development in acute leukemia. J. Clin. Invest. 126, 4404\u20134416 (2016).","journal-title":"J. Clin. Invest."},{"key":"2096_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41994-0","volume":"14","author":"H Mumme","year":"2023","unstructured":"Mumme, H. et al. Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia. Nat. Commun. 14, 6209 (2023).","journal-title":"Nat. Commun."},{"key":"2096_CR93","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jama.2022.14578","volume":"328","author":"MA Sekeres","year":"2022","unstructured":"Sekeres, M. A. & Taylor, J. Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA 328, 872\u2013880 (2022).","journal-title":"JAMA"},{"key":"2096_CR94","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ng.3742","volume":"49","author":"H Makishima","year":"2017","unstructured":"Makishima, H. et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat. Genet. 49, 204\u2013212 (2017).","journal-title":"Nat. Genet."},{"key":"2096_CR95","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1182\/blood-2016-10-696062","volume":"129","author":"A Shastri","year":"2017","unstructured":"Shastri, A., Will, B., Steidl, U. & Verma, A. Stem and progenitor cell alterations in myelodysplastic syndromes. Blood 129, 1586\u20131594 (2017).","journal-title":"Blood"},{"key":"2096_CR96","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/leu.2013.180","volume":"27","author":"Y Wei","year":"2013","unstructured":"Wei, Y. et al. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia 27, 1832\u20131840 (2013).","journal-title":"Leukemia"},{"key":"2096_CR97","doi-asserted-by":"publisher","first-page":"e71120","DOI":"10.1371\/journal.pone.0071120","volume":"8","author":"S Dimicoli","year":"2013","unstructured":"Dimicoli, S. et al. Overexpression of the Toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes. PLoS ONE 8, e71120 (2013).","journal-title":"PLoS ONE"},{"key":"2096_CR98","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ccr.2013.05.006","volume":"24","author":"GW Rhyasen","year":"2013","unstructured":"Rhyasen, G. W. et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 24, 90\u2013104 (2013).","journal-title":"Cancer Cell"},{"key":"2096_CR99","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/leu.2015.69","volume":"29","author":"I Ganan-Gomez","year":"2015","unstructured":"Ganan-Gomez, I. et al. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia 29, 1458\u20131469 (2015).","journal-title":"Leukemia"},{"key":"2096_CR100","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1365-2141.2007.06923.x","volume":"140","author":"DL Stirewalt","year":"2008","unstructured":"Stirewalt, D. L. et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? Br. J. Haematol. 140, 444\u2013453 (2008).","journal-title":"Br. J. Haematol."},{"key":"2096_CR101","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1158\/2643-3230.BCD-20-0161","volume":"2","author":"SA Mian","year":"2021","unstructured":"Mian, S. A. et al. Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells. Blood Cancer Discov. 2, 135\u2013145 (2021).","journal-title":"Blood Cancer Discov."},{"key":"2096_CR102","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2643-3230.BCD-21-0128","volume":"3","author":"T Guess","year":"2022","unstructured":"Guess, T. et al. Distinct patterns of clonal evolution drive myelodysplastic syndrome progression to secondary acute myeloid leukemia. Blood Cancer Discov. 3, 316\u2013329 (2022).","journal-title":"Blood Cancer Discov."},{"key":"2096_CR103","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2767-9764.CRC-23-0389","volume":"4","author":"I Campillo-Marcos","year":"2024","unstructured":"Campillo-Marcos, I. et al. Single-cell multiomics analysis of myelodysplastic syndromes and clinical response to hypomethylating therapy. Cancer Res. Commun. 4, 365\u2013377 (2024).","journal-title":"Cancer Res. Commun."},{"key":"2096_CR104","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood.2023023166","volume":"143","author":"JJ Rodriguez-Sevilla","year":"2024","unstructured":"Rodriguez-Sevilla, J. J. & Colla, S. T-cell dysfunctions in myelodysplastic syndromes. Blood 143, 1329\u20131343 (2024).","journal-title":"Blood"},{"key":"2096_CR105","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","volume":"402","author":"U Platzbecker","year":"2023","unstructured":"Platzbecker, U. et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet 402, 373\u2013385 (2023).","journal-title":"Lancet"},{"key":"2096_CR106","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.blre.2017.08.006","volume":"32","author":"E Vadillo","year":"2018","unstructured":"Vadillo, E., Dorantes-Acosta, E., Pelayo, R. & Schnoor, M. T cell acute lymphoblastic leukemia (T-ALL): new insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. Blood Rev. 32, 36\u201351 (2018).","journal-title":"Blood Rev."},{"key":"2096_CR107","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","volume":"632","author":"P Polonen","year":"2024","unstructured":"Polonen, P. et al. The genomic basis of childhood T-lineage acute lymphoblastic leukaemia. Nature 632, 1082\u20131091 (2024).","journal-title":"Nature"},{"key":"2096_CR108","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1101\/gad.10.15.1930","volume":"10","author":"L Girard","year":"1996","unstructured":"Girard, L. et al. Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTVD\/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis. Genes Dev. 10, 1930\u20131944 (1996).","journal-title":"Genes Dev."},{"key":"2096_CR109","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.cell.2013.05.041","volume":"153","author":"B King","year":"2013","unstructured":"King, B. et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 153, 1552\u20131566 (2013).","journal-title":"Cell"},{"key":"2096_CR110","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1182\/blood-2013-08-522698","volume":"123","author":"JE Roderick","year":"2014","unstructured":"Roderick, J. E. et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 123, 1040\u20131050 (2014).","journal-title":"Blood"},{"key":"2096_CR111","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269\u2013271 (2004).","journal-title":"Science"},{"key":"2096_CR112","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrc.2016.63","volume":"16","author":"L Belver","year":"2016","unstructured":"Belver, L. & Ferrando, A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat. Rev. Cancer 16, 494\u2013507 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"2096_CR113","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211\u20131218 (2017).","journal-title":"Nat. Genet."},{"key":"2096_CR114","doi-asserted-by":"publisher","first-page":"E1016","DOI":"10.1073\/pnas.1520245113","volume":"113","author":"TA Triplett","year":"2016","unstructured":"Triplett, T. A. et al. Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation. Proc. Natl Acad. Sci. USA 113, E1016\u2013E1025 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2096_CR115","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1182\/blood.2020007145","volume":"136","author":"A Lyu","year":"2020","unstructured":"Lyu, A. et al. Tumor-associated myeloid cells provide critical support for T-ALL. Blood 136, 1837\u20131850 (2020).","journal-title":"Blood"},{"key":"2096_CR116","doi-asserted-by":"publisher","first-page":"106442","DOI":"10.1016\/j.leukres.2020.106442","volume":"97","author":"H Maganti","year":"2020","unstructured":"Maganti, H. et al. Plerixafor in combination with chemotherapy and\/or hematopoietic cell transplantation to treat acute leukemia: a systematic review and metanalysis of preclinical and clinical studies. Leuk. Res. 97, 106442 (2020).","journal-title":"Leuk. Res."},{"key":"2096_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41925-z","volume":"14","author":"A Lyu","year":"2023","unstructured":"Lyu, A. et al. Integrin signaling is critical for myeloid-mediated support of T-cell acute lymphoblastic leukemia. Nat. Commun. 14, 6270 (2023).","journal-title":"Nat. Commun."},{"key":"2096_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85034-7","volume":"11","author":"M Caron","year":"2021","unstructured":"Caron, M. et al. Publisher correction: single-cell analysis of childhood leukemia reveals a link between developmental states and ribosomal protein expression as a source of intra-individual heterogeneity. Sci. Rep. 11, 5414 (2021).","journal-title":"Sci. Rep."},{"key":"2096_CR119","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nm.4505","volume":"24","author":"Z Good","year":"2018","unstructured":"Good, Z. et al. Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse. Nat. Med. 24, 474\u2013483 (2018).","journal-title":"Nat. Med."},{"key":"2096_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26771-1","volume":"12","author":"H Contreras-Trujillo","year":"2021","unstructured":"Contreras-Trujillo, H. et al. Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses. Nat. Commun. 12, 6522 (2021).","journal-title":"Nat. Commun."},{"key":"2096_CR121","doi-asserted-by":"publisher","first-page":"e700","DOI":"10.1097\/HS9.0000000000000700","volume":"6","author":"S Meyers","year":"2022","unstructured":"Meyers, S. et al. Monitoring of leukemia clones in B-cell acute lymphoblastic leukemia at diagnosis and during treatment by single-cell DNA amplicon sequencing. Hemasphere 6, e700 (2022).","journal-title":"Hemasphere"},{"key":"2096_CR122","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady, S. W. et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat. Genet. 54, 1376\u20131389 (2022).","journal-title":"Nat. Genet."},{"key":"2096_CR123","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1182\/blood.2020006287","volume":"137","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood 137, 471\u2013484 (2021).","journal-title":"Blood"},{"key":"2096_CR124","doi-asserted-by":"publisher","first-page":"e2101447","DOI":"10.1002\/advs.202101447","volume":"8","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. Single-cell RNA-seq of T cells in B-ALL patients reveals an exhausted subset with remarkable heterogeneity. Adv. Sci. 8, e2101447 (2021).","journal-title":"Adv. Sci."},{"key":"2096_CR125","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/s41375-018-0360-1","volume":"33","author":"H Hohtari","year":"2019","unstructured":"Hohtari, H. et al. Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL. Leukemia 33, 1570\u20131582 (2019).","journal-title":"Leukemia"},{"key":"2096_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16152-z","volume":"12","author":"R Hunter","year":"2022","unstructured":"Hunter, R. et al. B-cell acute lymphoblastic leukemia promotes an immune suppressive microenvironment that can be overcome by IL-12. Sci. Rep. 12, 11870 (2022).","journal-title":"Sci. Rep."},{"key":"2096_CR127","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1182\/blood.2020009871","volume":"138","author":"C Duault","year":"2021","unstructured":"Duault, C. et al. Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. Blood 138, 1465\u20131480 (2021).","journal-title":"Blood"},{"key":"2096_CR128","doi-asserted-by":"publisher","first-page":"e140179","DOI":"10.1172\/jci.insight.140179","volume":"5","author":"JK Bailur","year":"2020","unstructured":"Bailur, J. K. et al. Risk-associated alterations in marrow T cells in pediatric leukemia. JCI Insight 5, e140179 (2020).","journal-title":"JCI Insight"},{"key":"2096_CR129","doi-asserted-by":"publisher","first-page":"e006649","DOI":"10.1136\/jitc-2022-006649","volume":"11","author":"A Kumar","year":"2023","unstructured":"Kumar, A. et al. Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia. J. Immunother. Cancer 11, e006649 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2096_CR130","first-page":"2073","volume":"109","author":"MWE Smeets","year":"2024","unstructured":"Smeets, M. W. E. et al. B-cell precursor acute lymphoblastic leukemia elicits an interferon-\u03b1\/\u03b2 response in bone marrow-derived mesenchymal stroma. Haematologica 109, 2073\u20132084 (2024).","journal-title":"Haematologica"},{"key":"2096_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16447-7","volume":"11","author":"S Swaminathan","year":"2020","unstructured":"Swaminathan, S. et al. MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. Nat. Commun. 11, 2860 (2020).","journal-title":"Nat. Commun."},{"key":"2096_CR132","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1182\/bloodadvances.2021004908","volume":"5","author":"JM Magenau","year":"2021","unstructured":"Magenau, J. M. et al. Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Adv. 5, 5047\u20135056 (2021).","journal-title":"Blood Adv."},{"key":"2096_CR133","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm.4484","volume":"24","author":"NR Mathew","year":"2018","unstructured":"Mathew, N. R. et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat. Med. 24, 282\u2013291 (2018).","journal-title":"Nat. Med."},{"key":"2096_CR134","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood-2003-09-3344","volume":"105","author":"O Alpdogan","year":"2005","unstructured":"Alpdogan, O. et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 105, 865\u2013873 (2005).","journal-title":"Blood"},{"key":"2096_CR135","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1182\/blood-2013-11-540625","volume":"123","author":"AJ de Smith","year":"2014","unstructured":"de Smith, A. J. et al. The role of KIR genes and their cognate HLA class I ligands in childhood acute lymphoblastic leukemia. Blood 123, 2497\u20132503 (2014).","journal-title":"Blood"},{"key":"2096_CR136","doi-asserted-by":"publisher","first-page":"e0227314","DOI":"10.1371\/journal.pone.0227314","volume":"15","author":"L Valenzuela-Vazquez","year":"2020","unstructured":"Valenzuela-Vazquez, L. et al. Functional characterization of NK cells in Mexican pediatric patients with acute lymphoblastic leukemia: report from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia. PLoS ONE 15, e0227314 (2020).","journal-title":"PLoS ONE"},{"key":"2096_CR137","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1038\/s41588-024-01929-x","volume":"56","author":"A Stiff","year":"2024","unstructured":"Stiff, A. et al. Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nat. Genet. 56, 2434\u20132446 (2024).","journal-title":"Nat. Genet."},{"key":"2096_CR138","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau, D. A. et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526, 525\u2013530 (2015).","journal-title":"Nature"},{"key":"2096_CR139","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.celrep.2016.01.042","volume":"14","author":"G Galletti","year":"2016","unstructured":"Galletti, G. et al. Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression. Cell Rep. 14, 1748\u20131760 (2016).","journal-title":"Cell Rep."},{"key":"2096_CR140","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","volume":"54","author":"BA Knisbacher","year":"2022","unstructured":"Knisbacher, B. A. et al. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat. Genet. 54, 1664\u20131674 (2022).","journal-title":"Nat. Genet."},{"key":"2096_CR141","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.ccell.2016.10.005","volume":"30","author":"L Wang","year":"2016","unstructured":"Wang, L. et al. Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia. Cancer Cell 30, 750\u2013763 (2016).","journal-title":"Cancer Cell"},{"key":"2096_CR142","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1182\/blood-2007-05-089409","volume":"110","author":"A Burkle","year":"2007","unstructured":"Burkle, A. et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 110, 3316\u20133325 (2007).","journal-title":"Blood"},{"key":"2096_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113011","volume":"42","author":"P Bachireddy","year":"2023","unstructured":"Bachireddy, P. et al. Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep. 42, 113011 (2023).","journal-title":"Cell Rep."},{"key":"2096_CR144","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1182\/blood.2021013926","volume":"139","author":"N Purroy","year":"2022","unstructured":"Purroy, N. et al. Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood 139, 2252\u20132256 (2022).","journal-title":"Blood"},{"key":"2096_CR145","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.hemonc.2021.02.003","volume":"15","author":"F Yassine","year":"2022","unstructured":"Yassine, F. et al. Efficacy of allogeneic hematopoietic cell transplantation in patients with chronic phase CML resistant or intolerant to tyrosine kinase inhibitors. Hematol. Oncol. Stem Cell Ther. 15, 36\u201343 (2022).","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"2096_CR146","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"JJ Molldrem","year":"2000","unstructured":"Molldrem, J. J. et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6, 1018\u20131023 (2000).","journal-title":"Nat. Med."},{"key":"2096_CR147","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm.4336","volume":"23","author":"A Giustacchini","year":"2017","unstructured":"Giustacchini, A. et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat. Med. 23, 692\u2013702 (2017).","journal-title":"Nat. Med."},{"key":"2096_CR148","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/s41375-019-0684-5","volume":"34","author":"R Kinstrie","year":"2020","unstructured":"Kinstrie, R. et al. CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia 34, 1613\u20131625 (2020).","journal-title":"Leukemia"},{"key":"2096_CR149","doi-asserted-by":"publisher","first-page":"e152585","DOI":"10.1172\/JCI152585","volume":"132","author":"J Huuhtanen","year":"2022","unstructured":"Huuhtanen, J. et al. IFN-\u03b1 with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia. J. Clin. Invest. 132, e152585 (2022).","journal-title":"J. Clin. Invest."},{"key":"2096_CR150","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1158\/2643-3230.BCD-22-0176","volume":"4","author":"JC Balandran","year":"2023","unstructured":"Balandran, J. C., Lasry, A. & Aifantis, I. The role of inflammation in the initiation and progression of myeloid neoplasms. Blood Cancer Discov. 4, 254\u2013266 (2023).","journal-title":"Blood Cancer Discov."},{"key":"2096_CR151","doi-asserted-by":"publisher","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","volume":"366","author":"S Jaiswal","year":"2019","unstructured":"Jaiswal, S. & Ebert, B. L. Clonal hematopoiesis in human aging and disease. Science 366, eaan4673 (2019).","journal-title":"Science"},{"key":"2096_CR152","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.it.2017.01.004","volume":"38","author":"S Boettcher","year":"2017","unstructured":"Boettcher, S. & Manz, M. G. Regulation of inflammation- and infection-driven hematopoiesis. Trends Immunol. 38, 345\u2013357 (2017).","journal-title":"Trends Immunol."},{"key":"2096_CR153","doi-asserted-by":"publisher","first-page":"1000996","DOI":"10.3389\/fimmu.2022.1000996","volume":"13","author":"M Luciano","year":"2022","unstructured":"Luciano, M., Krenn, P. W. & Horejs-Hoeck, J. The cytokine network in acute myeloid leukemia. Front. Immunol. 13, 1000996 (2022).","journal-title":"Front. Immunol."},{"key":"2096_CR154","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","volume":"115","author":"PA Beer","year":"2010","unstructured":"Beer, P. A. et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115, 2891\u20132900 (2010).","journal-title":"Blood"},{"key":"2096_CR155","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/blood-2018-03-784116","volume":"132","author":"L Barreyro","year":"2018","unstructured":"Barreyro, L., Chlon, T. M. & Starczynowski, D. T. Chronic immune response dysregulation in MDS pathogenesis. Blood 132, 1553\u20131560 (2018).","journal-title":"Blood"},{"key":"2096_CR156","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1038\/s41375-023-02055-z","volume":"37","author":"J Xie","year":"2023","unstructured":"Xie, J. et al. STING activation in TET2-mutated hematopoietic stem\/progenitor cells contributes to the increased self-renewal and neoplastic transformation. Leukemia 37, 2457\u20132467 (2023).","journal-title":"Leukemia"},{"key":"2096_CR157","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1182\/blood.V100.10.3553","volume":"100","author":"WK Hofmann","year":"2002","unstructured":"Hofmann, W. K. et al. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 100, 3553\u20133560 (2002).","journal-title":"Blood"},{"key":"2096_CR158","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/leu.2010.31","volume":"24","author":"A Pellagatti","year":"2010","unstructured":"Pellagatti, A. et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 24, 756\u2013764 (2010).","journal-title":"Leukemia"},{"key":"2096_CR159","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3390\/cells8080854","volume":"8","author":"F Perner","year":"2019","unstructured":"Perner, F., Perner, C., Ernst, T. & Heidel, F. H. Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. Cells 8, 854 (2019).","journal-title":"Cells"},{"key":"2096_CR160","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1021\/acsmedchemlett.0c00255","volume":"11","author":"VR Gummadi","year":"2020","unstructured":"Gummadi, V. R. et al. Discovery of CA-4948, an orally bioavailable IRAK4 inhibitor for treatment of hematologic malignancies. ACS Med. Chem. Lett. 11, 2374\u20132381 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"2096_CR161","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1182\/blood.2022018718","volume":"142","author":"J Bennett","year":"2023","unstructured":"Bennett, J. et al. Paralog-specific signaling by IRAK1\/4 maintains MyD88-independent functions in MDS\/AML. Blood 142, 989\u20131007 (2023).","journal-title":"Blood"},{"key":"2096_CR162","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41586-018-0125-z","volume":"557","author":"M Meisel","year":"2018","unstructured":"Meisel, M. et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557, 580\u2013584 (2018).","journal-title":"Nature"},{"key":"2096_CR163","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.exphem.2017.08.001","volume":"55","author":"AH Cull","year":"2017","unstructured":"Cull, A. H., Snetsinger, B., Buckstein, R., Wells, R. A. & Rauh, M. J. Tet2 restrains inflammatory gene expression in macrophages. Exp. Hematol. 55, 56\u201370 (2017).","journal-title":"Exp. Hematol."},{"key":"2096_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44270-3","volume":"15","author":"F Wang","year":"2024","unstructured":"Wang, F. et al. Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. Nat. Commun. 15, 203 (2024).","journal-title":"Nat. Commun."},{"key":"2096_CR165","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/bjh.16523","volume":"190","author":"L Beneforti","year":"2020","unstructured":"Beneforti, L. et al. Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche. Br. J. Haematol. 190, 262\u2013273 (2020).","journal-title":"Br. J. Haematol."},{"key":"2096_CR166","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41556-022-01050-3","volume":"25","author":"X Xu","year":"2023","unstructured":"Xu, X. et al. PD-1 signalling defines and protects leukaemic stem cells from T cell receptor-induced cell death in T cell acute lymphoblastic leukaemia. Nat. Cell Biol. 25, 170\u2013182 (2023).","journal-title":"Nat. Cell Biol."},{"key":"2096_CR167","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3390\/cancers13071536","volume":"13","author":"A Pastorczak","year":"2021","unstructured":"Pastorczak, A., Domka, K., Fidyt, K., Poprzeczko, M. & Firczuk, M. Mechanisms of immune evasion in acute lymphoblastic leukemia. Cancers 13, 1536 (2021).","journal-title":"Cancers"},{"key":"2096_CR168","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.cell.2019.01.008","volume":"176","author":"MF Sanmamed","year":"2019","unstructured":"Sanmamed, M. F. & Chen, L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 176, 677 (2019).","journal-title":"Cell"},{"key":"2096_CR169","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/S1471-4906(03)00099-1","volume":"24","author":"NR Hegde","year":"2003","unstructured":"Hegde, N. R., Chevalier, M. S. & Johnson, D. C. Viral inhibition of MHC class II antigen presentation. Trends Immunol. 24, 278\u2013285 (2003).","journal-title":"Trends Immunol."},{"key":"2096_CR170","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.chom.2016.10.007","volume":"20","author":"E Bayer-Santos","year":"2016","unstructured":"Bayer-Santos, E. et al. The Salmonella effector SteD mediates MARCH8-dependent ubiquitination of MHC II molecules and inhibits T cell activation. Cell Host Microbe 20, 584\u2013595 (2016).","journal-title":"Cell Host Microbe"},{"key":"2096_CR171","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1158\/2643-3230.BCD-21-0207","volume":"3","author":"K Eagle","year":"2022","unstructured":"Eagle, K. et al. Transcriptional plasticity drives leukemia immune escape. Blood Cancer Discov. 3, 394\u2013409 (2022).","journal-title":"Blood Cancer Discov."},{"key":"2096_CR172","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1038\/s41375-022-01705-y","volume":"36","author":"SK Saini","year":"2022","unstructured":"Saini, S. K. et al. Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies. Leukemia 36, 2734\u20132738 (2022).","journal-title":"Leukemia"},{"key":"2096_CR173","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger, T. & Abdul-Hay, M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 7, e577 (2017).","journal-title":"Blood Cancer J."},{"key":"2096_CR174","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/sj.leu.2404578","volume":"21","author":"MW Jansen","year":"2007","unstructured":"Jansen, M. W. et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia 21, 633\u2013641 (2007).","journal-title":"Leukemia"},{"key":"2096_CR175","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nri2454","volume":"9","author":"FD Batista","year":"2009","unstructured":"Batista, F. D. & Harwood, N. E. The who, how and where of antigen presentation to B cells. Nat. Rev. Immunol. 9, 15\u201327 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"2096_CR176","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.celrep.2013.03.003","volume":"3","author":"F Rapino","year":"2013","unstructured":"Rapino, F. et al. C\/EBP\u03b1 induces highly efficient macrophage transdifferentiation of B lymphoma and leukemia cell lines and impairs their tumorigenicity. Cell Rep. 3, 1153\u20131163 (2013).","journal-title":"Cell Rep."},{"key":"2096_CR177","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0092-8674(04)00419-2","volume":"117","author":"H Xie","year":"2004","unstructured":"Xie, H., Ye, M., Feng, R. & Graf, T. Stepwise reprogramming of B cells into macrophages. Cell 117, 663\u2013676 (2004).","journal-title":"Cell"},{"key":"2096_CR178","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1073\/pnas.1413383112","volume":"112","author":"JS McClellan","year":"2015","unstructured":"McClellan, J. S., Dove, C., Gentles, A. J., Ryan, C. E. & Majeti, R. Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages. Proc. Natl Acad. Sci. USA 112, 4074\u20134079 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2096_CR179","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.immuni.2020.01.014","volume":"52","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Blockade of the phagocytic receptor MerTK on tumor-associated macrophages enhances P2X7R-dependent STING activation by tumor-derived cGAMP. Immunity 52, 357\u2013373 (2020).","journal-title":"Immunity"},{"key":"2096_CR180","doi-asserted-by":"publisher","first-page":"e153157","DOI":"10.1172\/JCI153157","volume":"132","author":"JA Moore","year":"2022","unstructured":"Moore, J. A. et al. LC3-associated phagocytosis in bone marrow macrophages suppresses acute myeloid leukemia progression through STING activation. J. Clin. Invest. 132, e153157 (2022).","journal-title":"J. Clin. Invest."},{"key":"2096_CR181","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286\u2013299 (2009).","journal-title":"Cell"},{"key":"2096_CR182","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41556-022-00849-4","volume":"24","author":"S Pinho","year":"2022","unstructured":"Pinho, S. et al. VCAM1 confers innate immune tolerance on haematopoietic and leukaemic stem cells. Nat. Cell Biol. 24, 290\u2013298 (2022).","journal-title":"Nat. Cell Biol."},{"key":"2096_CR183","doi-asserted-by":"publisher","first-page":"882531","DOI":"10.3389\/fonc.2022.882531","volume":"12","author":"M Gomez-Llobell","year":"2022","unstructured":"Gomez-Llobell, M., Peleteiro Raindo, A., Climent Medina, J., Gomez Centurion, I. & Mosquera Orgueira, A. Immune checkpoint inhibitors in acute myeloid leukemia: a meta-analysis. Front. Oncol. 12, 882531 (2022).","journal-title":"Front. Oncol."},{"key":"2096_CR184","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim, M. Y. et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173, 1439\u20131453 (2018).","journal-title":"Cell"},{"key":"2096_CR185","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41417-021-00418-1","volume":"29","author":"M Sheykhhasan","year":"2022","unstructured":"Sheykhhasan, M., Manoochehri, H. & Dama, P. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer Gene Ther. 29, 1080\u20131096 (2022).","journal-title":"Cancer Gene Ther."},{"key":"2096_CR186","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"2096_CR187","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41590-022-01314-y","volume":"23","author":"MT Witkowski","year":"2022","unstructured":"Witkowski, M. T. et al. NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia. Nat. Immunol. 23, 1424\u20131432 (2022).","journal-title":"Nat. Immunol."},{"key":"2096_CR188","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41375-019-0580-z","volume":"34","author":"M Asnani","year":"2020","unstructured":"Asnani, M. et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia 34, 1202\u20131207 (2020).","journal-title":"Leukemia"},{"key":"2096_CR189","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/cyto.b.21879","volume":"98","author":"SH Park","year":"2020","unstructured":"Park, S. H. et al. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis. Cytometry B Clin. Cytom. 98, 336\u2013347 (2020).","journal-title":"Cytometry B Clin. Cytom."},{"key":"2096_CR190","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","volume":"122","author":"A Mardiros","year":"2013","unstructured":"Mardiros, A. et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 122, 3138\u20133148 (2013).","journal-title":"Blood"},{"key":"2096_CR191","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang, J. et al. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J. Hematol. Oncol. 11, 7 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2096_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101121","volume":"31","author":"NE Petty","year":"2023","unstructured":"Petty, N. E. et al. Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem\/progenitor cells in nonhuman primates. Mol. Ther. Methods Clin. Dev. 31, 101121 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2096_CR193","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","volume":"621","author":"G Casirati","year":"2023","unstructured":"Casirati, G. et al. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. Nature 621, 404\u2013414 (2023).","journal-title":"Nature"},{"key":"2096_CR194","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","volume":"30","author":"AS Bhagwat","year":"2024","unstructured":"Bhagwat, A. S. et al. Cytokine-mediated CAR T therapy resistance in AML. Nat. Med. 30, 3697\u20133708 (2024).","journal-title":"Nat. Med."},{"key":"2096_CR195","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41409-023-02180-4","volume":"59","author":"N Albinger","year":"2024","unstructured":"Albinger, N. et al. Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia. Bone Marrow Transplant. 59, 489\u2013495 (2024).","journal-title":"Bone Marrow Transplant."},{"key":"2096_CR196","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial. Nat. Med. 30, 772\u2013784 (2024).","journal-title":"Nat. Med."},{"key":"2096_CR197","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2096_CR198","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1182\/bloodadvances.2022007405","volume":"7","author":"AG Mansour","year":"2023","unstructured":"Mansour, A. G. et al. Off-the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia. Blood Adv. 7, 6225\u20136239 (2023).","journal-title":"Blood Adv."},{"key":"2096_CR199","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40164-022-00263-4","volume":"11","author":"X Yang","year":"2022","unstructured":"Yang, X., Ma, L., Zhang, X., Huang, L. & Wei, J. Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Exp. Hematol. Oncol. 11, 11 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"2096_CR200","doi-asserted-by":"publisher","first-page":"103164","DOI":"10.1016\/j.critrevonc.2020.103164","volume":"157","author":"S Taghiloo","year":"2021","unstructured":"Taghiloo, S. & Asgarian-Omran, H. Immune evasion mechanisms in acute myeloid leukemia: a focus on immune checkpoint pathways. Crit. Rev. Oncol. Hematol. 157, 103164 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2096_CR201","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1007\/s11864-023-01129-5","volume":"24","author":"S Taghiloo","year":"2023","unstructured":"Taghiloo, S. & Asgarian-Omran, H. Current approaches of immune checkpoint therapy in chronic lymphocytic leukemia. Curr. Treat. Options Oncol. 24, 1408\u20131438 (2023).","journal-title":"Curr. Treat. Options Oncol."},{"key":"2096_CR202","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s42003-023-05120-6","volume":"6","author":"H Fan","year":"2023","unstructured":"Fan, H. et al. Single-cell chromatin accessibility profiling of acute myeloid leukemia reveals heterogeneous lineage composition upon therapy-resistance. Commun. Biol. 6, 765 (2023).","journal-title":"Commun. Biol."},{"key":"2096_CR203","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","volume":"123","author":"GS Laszlo","year":"2014","unstructured":"Laszlo, G. S. et al. Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 123, 554\u2013561 (2014).","journal-title":"Blood"},{"key":"2096_CR204","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.3324\/haematol.2018.202069","volume":"104","author":"GS Laszlo","year":"2019","unstructured":"Laszlo, G. S. et al. Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33\/CD3 BiTE AMG 330. Haematologica 104, e59\u2013e62 (2019).","journal-title":"Haematologica"},{"key":"2096_CR205","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.2","volume":"7","author":"SS Hoseini","year":"2017","unstructured":"Hoseini, S. S. & Cheung, N. K. Acute myeloid leukemia targets for bispecific antibodies. Blood Cancer J. 7, e522 (2017).","journal-title":"Blood Cancer J."},{"key":"2096_CR206","doi-asserted-by":"publisher","unstructured":"Sumit Gupta, P. D. et al. Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2411680 (2024).","DOI":"10.1056\/NEJMoa2411680"},{"key":"2096_CR207","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","volume":"55","author":"M Zhu","year":"2016","unstructured":"Zhu, M. et al. Blinatumomab, a bispecific T-cell engager (BiTE) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications. Clin. Pharmacokinet. 55, 1271\u20131288 (2016).","journal-title":"Clin. Pharmacokinet."},{"key":"2096_CR208","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1158\/1078-0432.CCR-13-0505","volume":"19","author":"A Wiernik","year":"2013","unstructured":"Wiernik, A. et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16\u2009\u00d7\u200933 bispecific killer cell engager and ADAM17 inhibition. Clin. Cancer Res. 19, 3844\u20133855 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2096_CR209","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","volume":"112","author":"HJ Kolb","year":"2008","unstructured":"Kolb, H. J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112, 4371\u20134383 (2008).","journal-title":"Blood"},{"key":"2096_CR210","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/TP.0b013e3182481113","volume":"93","author":"F Stolzel","year":"2012","unstructured":"Stolzel, F. et al. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation. Transplantation 93, 744\u2013749 (2012).","journal-title":"Transplantation"},{"key":"2096_CR211","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1349-7006.2006.00356.x","volume":"98","author":"K Masuda","year":"2007","unstructured":"Masuda, K. et al. Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts. Cancer Sci. 98, 102\u2013108 (2007).","journal-title":"Cancer Sci."},{"key":"2096_CR212","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood.2023021815","volume":"143","author":"A Mathioudaki","year":"2024","unstructured":"Mathioudaki, A. et al. The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature. Blood 143, 1269\u20131281 (2024).","journal-title":"Blood"},{"key":"2096_CR213","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1005031","volume":"13","author":"MU Mushtaq","year":"2022","unstructured":"Mushtaq, M. U. et al. Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Front. Immunol. 13, 1005031 (2022).","journal-title":"Front. Immunol."},{"key":"2096_CR214","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1182\/blood.2022015474","volume":"140","author":"D Wang","year":"2022","unstructured":"Wang, D. et al. GARP-mediated active TGF-\u03b21 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT. Blood 140, 2788\u20132804 (2022).","journal-title":"Blood"},{"key":"2096_CR215","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3324\/haematol.2019.227371","volume":"106","author":"RM Saliba","year":"2021","unstructured":"Saliba, R. M. et al. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica 106, 269\u2013274 (2021).","journal-title":"Haematologica"},{"key":"2096_CR216","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41375-021-01349-4","volume":"36","author":"SO Ciurea","year":"2022","unstructured":"Ciurea, S. O. et al. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia 36, 155\u2013164 (2022).","journal-title":"Leukemia"},{"key":"2096_CR217","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"2096_CR218","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"2096_CR219","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12984","volume":"505","author":"SJ Morrison","year":"2014","unstructured":"Morrison, S. J. & Scadden, D. T. The bone marrow niche for haematopoietic stem cells. Nature 505, 327\u2013334 (2014).","journal-title":"Nature"},{"key":"2096_CR220","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.cell.2008.01.038","volume":"132","author":"SJ Morrison","year":"2008","unstructured":"Morrison, S. J. & Spradling, A. C. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 132, 598\u2013611 (2008).","journal-title":"Cell"},{"key":"2096_CR221","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41580-019-0103-9","volume":"20","author":"S Pinho","year":"2019","unstructured":"Pinho, S. & Frenette, P. S. Haematopoietic stem cell activity and interactions with the niche. Nat. Rev. Mol. Cell Biol. 20, 303\u2013320 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2096_CR222","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2096_CR223","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","volume":"133","author":"R Zeiser","year":"2019","unstructured":"Zeiser, R. & Vago, L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood 133, 1290\u20131297 (2019).","journal-title":"Blood"},{"key":"2096_CR224","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1182\/blood-2016-10-746909","volume":"129","author":"D Karpova","year":"2017","unstructured":"Karpova, D. et al. Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells. Blood 129, 2939\u20132949 (2017).","journal-title":"Blood"},{"key":"2096_CR225","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41551-024-01202-w","volume":"8","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. Targeted desialylation and cytolysis of tumour cells by fusing a sialidase to a bispecific T-cell engager. Nat. Biomed. Eng. 8, 499\u2013512 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"2096_CR226","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"2096_CR227","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez, H. F. et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. 361, 1249\u20131259 (2009).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02096-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02096-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02096-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T05:06:35Z","timestamp":1741064795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02096-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":227,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2096"],"URL":"https:\/\/doi.org\/10.1038\/s41590-025-02096-9","relation":{},"ISSN":["1529-2908","1529-2916"],"issn-type":[{"value":"1529-2908","type":"print"},{"value":"1529-2916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}